- Home
- SWIN vs SCYX Comparison
SWIN vs SCYX Comparison
Compare SWIN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- SCYX
- Stock Information
- Founded
- SWIN 2017
- SCYX 1999
- Country
- SWIN Hong Kong
- SCYX United States
- Employees
- SWIN N/A
- SCYX N/A
- Industry
- SWIN
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- SCYX Health Care
- Exchange
- SWIN Nasdaq
- SCYX Nasdaq
- Market Cap
- SWIN 214.1M
- SCYX 28.5M
- IPO Year
- SWIN 2023
- SCYX 2014
- Fundamental
- Price
- SWIN $3.93
- SCYX $0.70
- Analyst Decision
- SWIN
- SCYX
- Analyst Count
- SWIN 0
- SCYX 0
- Target Price
- SWIN N/A
- SCYX N/A
- AVG Volume (30 Days)
- SWIN 208.1K
- SCYX 187.5K
- Earning Date
- SWIN 08-21-2025
- SCYX 08-11-2025
- Dividend Yield
- SWIN N/A
- SCYX N/A
- EPS Growth
- SWIN N/A
- SCYX N/A
- EPS
- SWIN N/A
- SCYX N/A
- Revenue
- SWIN $3,316,000.00
- SCYX $2,630,000.00
- Revenue This Year
- SWIN $29.79
- SCYX $410.22
- Revenue Next Year
- SWIN $54.60
- SCYX $248.83
- P/E Ratio
- SWIN N/A
- SCYX N/A
- Revenue Growth
- SWIN N/A
- SCYX N/A
- 52 Week Low
- SWIN $1.16
- SCYX $0.66
- 52 Week High
- SWIN $4.40
- SCYX $2.21
- Technical
- Relative Strength Index (RSI)
- SWIN 62.05
- SCYX 41.70
- Support Level
- SWIN $3.70
- SCYX $0.67
- Resistance Level
- SWIN $3.99
- SCYX $0.74
- Average True Range (ATR)
- SWIN 0.35
- SCYX 0.04
- MACD
- SWIN -0.03
- SCYX 0.00
- Stochastic Oscillator
- SWIN 93.02
- SCYX 10.15
About SWIN Solowin Holdings
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.